ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB – Get Free Report) shares passed above its 50-day moving average during trading on Friday. The stock has a 50-day moving average of $113.47 and traded as high as $118.03. ProShares Ultra Nasdaq Biotechnology shares last traded at $117.7660, with a volume of 5,877 shares trading hands.
ProShares Ultra Nasdaq Biotechnology Stock Performance
The stock has a market capitalization of $101.28 million, a P/E ratio of 20.68 and a beta of 1.25. The business has a 50 day simple moving average of $113.47 and a 200-day simple moving average of $95.82.
ProShares Ultra Nasdaq Biotechnology’s stock is scheduled to split on Thursday, November 19th. The 2-1 split was recently announced. The newly issued shares will be payable to shareholders after the closing bell on Wednesday, November 18th.
Hedge Funds Weigh In On ProShares Ultra Nasdaq Biotechnology
A number of hedge funds have recently bought and sold shares of the company. Capital Investment Advisors LLC purchased a new position in shares of ProShares Ultra Nasdaq Biotechnology during the third quarter worth approximately $658,000. Kaizen Financial Strategies increased its stake in ProShares Ultra Nasdaq Biotechnology by 4.7% in the 1st quarter. Kaizen Financial Strategies now owns 5,565 shares of the exchange traded fund’s stock valued at $483,000 after buying an additional 250 shares during the period. Finally, Toth Financial Advisory Corp acquired a new position in ProShares Ultra Nasdaq Biotechnology in the third quarter valued at $118,000.
ProShares Ultra Nasdaq Biotechnology Company Profile
ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period. The Fund does not seek to achieve its stated investment objective over a period of time greater than one day.
Featured Stories
- Five stocks we like better than ProShares Ultra Nasdaq Biotechnology
- Airbnb Defied a Brutal Tech Sell-Off, But Can Its Post-Earnings Rally Last?
- MarketBeat Week in Review – 11/2 – 11/6
- Q3 Earnings Have Investors Wondering: Is Mercado Libre Finally a Buy?
- CVS Raised Its Outlook and Announced a Breakup—So Why Did the Stock Drop?
Receive News & Ratings for ProShares Ultra Nasdaq Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProShares Ultra Nasdaq Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
